UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Ceftolozane-tazobactam compared with levofloxacin in the treatment of complicated urinary-tract infections, including pyelonephritis: a randomised, double-blind, phase 3 trial (ASPECT-cUTI)

The Lancet (British edition), 2015-05, Vol.385 (9981), p.1949-1956

2015

Volltextzugriff (PDF)

Microbiology and Preclinical Review of Omadacycline

Clinical infectious diseases, 2019-08, Vol.69 (Supplement_1), p.S6-S15

2019

Volltextzugriff (PDF)

Omadacycline for Community-Acquired Bacterial Pneumonia

The New England journal of medicine, 2019-02, Vol.380 (6), p.517-527

2019

Volltextzugriff (PDF)

Ceftolozane/Tazobactam Plus Metronidazole for Complicated Intra-abdominal Infections in an Era of Multidrug Resistance: Results From a Randomized, Double-Blind, Phase 3 Trial (ASPECT-cIAI)

Clinical infectious diseases, 2015-05, Vol.60 (10), p.1462-1471

2015

Volltextzugriff (PDF)

Omadacycline for Acute Bacterial Skin and Skin-Structure Infections

The New England journal of medicine, 2019-02, Vol.380 (6), p.528-538

2019

Volltextzugriff (PDF)

Daptomycin Rapidly Penetrates a Staphylococcus epidermidis Biofilm

Antimicrobial Agents and Chemotherapy, 2009-08, Vol.53 (8), p.3505-3507

2009

Volltextzugriff (PDF)

Once-daily oral omadacycline versus twice-daily oral linezolid for acute bacterial skin and skin structure infections (OASIS-2): a phase 3, double-blind, multicentre, randomised, controlled, non-inferiority trial

The Lancet infectious diseases, 2019-10, Vol.19 (10), p.1080-1090

2019

Volltextzugriff (PDF)

Susceptibility relationship between vancomycin and daptomycin in Staphylococcus aureus : facts and assumptions

The Lancet infectious diseases, 2009-10, Vol.9 (10), p.617-624

2009

Volltextzugriff (PDF)

Efficacy of ceftolozane/tazobactam against urinary tract and intra-abdominal infections caused by ESBL-producing Escherichia coli and Klebsiella pneumoniae: a pooled analysis of Phase 3 clinical trials

Journal of antimicrobial chemotherapy, 2017-01, Vol.72 (1), p.268-272

2017

Volltextzugriff (PDF)

Pharmacokinetic-Pharmacodynamic Characterization of Omadacycline against Haemophilus influenzae Using a One-Compartment In Vitro Infection Model

Antimicrobial agents and chemotherapy, 2020-05, Vol.64 (6)

2020

Volltextzugriff (PDF)

Daptomycin: a lipopeptide antibiotic for the treatment of serious Gram-positive infections

Journal of antimicrobial chemotherapy, 2005-03, Vol.55 (3), p.283-288

2005

Volltextzugriff (PDF)

Characteristics and Outcomes of Complicated Intra-abdominal Infections Involving Pseudomonas aeruginosa from a Randomized, Double-Blind, Phase 3 Ceftolozane-Tazobactam Study

Antimicrobial agents and chemotherapy, 2016-07, Vol.60 (7), p.4387-4390

2016

Volltextzugriff (PDF)

Pharmacokinetic-Pharmacodynamic Target Attainment Analyses Evaluating Omadacycline Dosing Regimens for the Treatment of Patients with Community-Acquired Bacterial Pneumonia Arising from Streptococcus pneumoniae and Haemophilus influenzae

Antimicrobial agents and chemotherapy, 2023-04, Vol.67 (4), p.e0221321-e0221321

2023

Volltextzugriff (PDF)

Assessment of pharmacokinetics-pharmacodynamics to support omadacycline dosing regimens for the treatment of patients with acute bacterial skin and skin structure infections

Antimicrobial agents and chemotherapy, 2024-09, Vol.68 (9), p.e0128123

2024

Volltextzugriff (PDF)

Omadacycline vs moxifloxacin in adults with community-acquired bacterial pneumonia

International journal of infectious diseases, 2021-03, Vol.104, p.501-509

2021

Volltextzugriff (PDF)

Population Pharmacokinetic Analyses for Omadacycline Using Phase 1 and 3 Data

Antimicrobial agents and chemotherapy, 2020-06, Vol.64 (7)

2020

Volltextzugriff (PDF)

Pharmacokinetics-Pharmacodynamics of Tazobactam in Combination with Ceftolozane in an In Vitro Infection Model

Antimicrobial Agents and Chemotherapy, 2013-06, Vol.57 (6), p.2809-2814

2013

Volltextzugriff (PDF)

Pharmacological Basis of β-Lactamase Inhibitor Therapeutics: Tazobactam in Combination with Ceftolozane

Antimicrobial Agents and Chemotherapy, 2013-12, Vol.57 (12), p.5924-5930

2013

Volltextzugriff (PDF)

In Vitro Activity of Ceftolozane-Tazobactam against Anaerobic Organisms Identified during the ASPECT-cIAI Study

Antimicrobial agents and chemotherapy, 2016-01, Vol.60 (1), p.666-668

2016

Volltextzugriff (PDF)

Efficacy of ceftolozane/tazobactam versus levofloxacin in the treatment of complicated urinary tract infections (cUTIs) caused by levofloxacin-resistant pathogens: results from the ASPECT-cUTI trial

Journal of antimicrobial chemotherapy, 2016-07, Vol.71 (7), p.2014-2021

2016

Volltextzugriff (PDF)

Effects of daptomycin in combination with other antimicrobial agents: a review of in vitro and animal model studies

Journal of antimicrobial chemotherapy, 2009-12, Vol.64 (6), p.1130-1138

2009

Volltextzugriff (PDF)

Pharmacokinetics-Pharmacodynamics of Tazobactam in Combination with Piperacillin in an In Vitro Infection Model

Antimicrobial agents and chemotherapy, 2016-04, Vol.60 (4), p.2075-2080

2016

Volltextzugriff (PDF)

The Novel Aminomethylcycline Omadacycline Has High Specificity for the Primary Tetracycline-Binding Site on the Bacterial Ribosome

Antibiotics (Basel), 2016-09, Vol.5 (4), p.32-32

2016

Volltextzugriff (PDF)

Relationship between ceftolozane-tazobactam exposure and selection for Pseudomonas aeruginosa resistance in a hollow-fiber infection model

Antimicrobial agents and chemotherapy, 2014-10, Vol.58 (10), p.6024-6031

2014

Volltextzugriff (PDF)

The origin and maintenance of virulence for the human pathogenic fungus Cryptococcus neoformans

Microbes and Infection, 2003-06, Vol.5 (7), p.667-675

2003

Volltextzugriff (PDF)

1 – 25 von 87

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(85)
Mit Volltextzugriff
(79)

Publikationsform

Sprache

Englisch
(87)

Erscheinungsjahr

n.n

Thema

Science & Technology
(63)
Life Sciences & Biomedicine
(62)
Humans
(44)
Microbiology
(40)
Pharmacology & Pharmacy
(28)
Female
(26)
Infectious Diseases
(25)
Microbial Sensitivity Tests
(23)
Male
(22)
Biological And Medical Sciences
(21)
Anti-Bacterial Agents - Pharmacology
(19)
Medical Sciences
(17)
Middle Aged
(17)
Aged
(15)
Anti-Bacterial Agents - Therapeutic Use
(15)
Penicillanic Acid - Analogs & Derivatives
(15)
Adult
(13)
Anti-Bacterial Agents
(13)
Pharmacology
(12)
Omadacycline
(11)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Ceftolozane-tazobactam compared with levofloxacin in the treatment of complicated urinary-tract infections, including pyelonephritis: a randomised, double-blind, phase 3 trial (ASPECT-cUTI)

Microbiology and Preclinical Review of Omadacycline

Omadacycline for Community-Acquired Bacterial Pneumonia

Ceftolozane/Tazobactam Plus Metronidazole for Complicated Intra-abdominal Infections in an Era of Multidrug Resistance: Results From a Randomized, Double-Blind, Phase 3 Trial (ASPECT-cIAI)

Omadacycline for Acute Bacterial Skin and Skin-Structure Infections

Daptomycin Rapidly Penetrates a Staphylococcus epidermidis Biofilm

Once-daily oral omadacycline versus twice-daily oral linezolid for acute bacterial skin and skin structure infections (OASIS-2): a phase 3, double-blind, multicentre, randomised, controlled, non-inferiority trial

Susceptibility relationship between vancomycin and daptomycin in Staphylococcus aureus : facts and assumptions

Efficacy of ceftolozane/tazobactam against urinary tract and intra-abdominal infections caused by ESBL-producing Escherichia coli and Klebsiella pneumoniae: a pooled analysis of Phase 3 clinical trials

Pharmacokinetic-Pharmacodynamic Characterization of Omadacycline against Haemophilus influenzae Using a One-Compartment In Vitro Infection Model

Daptomycin: a lipopeptide antibiotic for the treatment of serious Gram-positive infections

Characteristics and Outcomes of Complicated Intra-abdominal Infections Involving Pseudomonas aeruginosa from a Randomized, Double-Blind, Phase 3 Ceftolozane-Tazobactam Study

Pharmacokinetic-Pharmacodynamic Target Attainment Analyses Evaluating Omadacycline Dosing Regimens for the Treatment of Patients with Community-Acquired Bacterial Pneumonia Arising from Streptococcus pneumoniae and Haemophilus influenzae

Assessment of pharmacokinetics-pharmacodynamics to support omadacycline dosing regimens for the treatment of patients with acute bacterial skin and skin structure infections

Omadacycline vs moxifloxacin in adults with community-acquired bacterial pneumonia

Population Pharmacokinetic Analyses for Omadacycline Using Phase 1 and 3 Data

Pharmacokinetics-Pharmacodynamics of Tazobactam in Combination with Ceftolozane in an In Vitro Infection Model

Pharmacological Basis of β-Lactamase Inhibitor Therapeutics: Tazobactam in Combination with Ceftolozane

In Vitro Activity of Ceftolozane-Tazobactam against Anaerobic Organisms Identified during the ASPECT-cIAI Study

Efficacy of ceftolozane/tazobactam versus levofloxacin in the treatment of complicated urinary tract infections (cUTIs) caused by levofloxacin-resistant pathogens: results from the ASPECT-cUTI trial

Effects of daptomycin in combination with other antimicrobial agents: a review of in vitro and animal model studies

Pharmacokinetics-Pharmacodynamics of Tazobactam in Combination with Piperacillin in an In Vitro Infection Model

The Novel Aminomethylcycline Omadacycline Has High Specificity for the Primary Tetracycline-Binding Site on the Bacterial Ribosome

Relationship between ceftolozane-tazobactam exposure and selection for Pseudomonas aeruginosa resistance in a hollow-fiber infection model

The origin and maintenance of virulence for the human pathogenic fungus Cryptococcus neoformans

Suchergebnisse filtern